News articles about Myovant Sciences (NASDAQ:MYOV) have been trending somewhat negative recently, Accern reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Myovant Sciences earned a daily sentiment score of -0.11 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.7903558434925 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Separately, Zacks Investment Research lowered Myovant Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, June 21st. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $18.20.
Shares of Myovant Sciences (NASDAQ:MYOV) traded down 3.44% during midday trading on Wednesday, hitting $10.67. The stock had a trading volume of 17,586 shares. Myovant Sciences has a 52-week low of $10.14 and a 52-week high of $15.50. The company’s 50 day moving average is $12.30 and its 200 day moving average is $11.88. The company’s market cap is $643.19 million.
TRADEMARK VIOLATION WARNING: This article was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://stocknewstimes.com/2017/07/19/somewhat-negative-media-coverage-somewhat-unlikely-to-affect-myovant-sciences-myov-share-price.html.
About Myovant Sciences
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.
Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.
